Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1997-04-30
1999-07-27
Mertz, Prema
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 857, 514 2, 514 8, 514885, 514895, A61K 3820, A61K 3821
Patent
active
059286369
ABSTRACT:
The present invention provides a combination of IL-12 and IFN.alpha. together with a pharmaceutically acceptable carrier useful for treatment and prophylaxis of infectious diseases, preferably chronic infectious diseases and more preferably viral infections, e.g. HSV, HIV, Hepatitis B, Hepatitis C, papilloma etc., bacterial infections, e.g. tuberculosis, salmonellosis, listeriosis, etc., and parasite infections, e.g. malaria, leishmaniasis, and schistosomiasis. These compositions are characterized by the synergistic interaction of IL-12 and IFN.alpha.. The present invention also provides the use of the above combination for the treatment and prophylaxis of infectious diseases.
REFERENCES:
patent: 5457038 (1995-10-01), Trinchieri et al.
patent: 5569454 (1996-10-01), Trinchieri et al.
patent: 5648072 (1997-07-01), Trinchieri et al.
patent: 5648467 (1997-07-01), Trinchieri et al.
Johnston et al., Science, vol. 260, pp. 1286-1293, 1993.
Fahey et al. Clin. Enp. Immunol. vol. 88, pp. 1-5, 1992.
Arai et al. Ann. Rev. Biochem. vol. 59, pp. 783-836, 1990.
Levy J. Microbiological Reviews, pp. 183-289, vol. 57, No. 1, 1993.
Carr, J.A. et al., Database Biosis, Biosciences Information Service, "Dual therapy with IL-12 and IFN--alpha provides a novel approach to the management of chronic viral disease." Antiviral Research 34(2) (1997) A65.
Chehimi, J., et al., Natural Killer (NK) Cell Stimulatory Factor Increases the Cytotoxic Activity of NK Cells from Both Healthy Donors and Human Immunodeficiency Virus-infected Patients, J. Exp. Med., 175, 789-796 (1992).
Rogerson, J., et al, Co-therapy with Suboptimal Doses of Interleukin-12 and Interferon-.alpha. Promotes Synergistic Protection against Herpes Virus Infection, Annals Of the New York Academy of Sciences, vol. 795, 354-356 (1996).
Lachgar, A. et al., Involvement of .alpha.-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment. Biomedicine & Pharmacotherapy, vol. 48, No. 2, 73-77, (1994).
Seder, R., et al., Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon .gamma. production and diminishes interleukin 4 inhibition of such priming, Proc. Natl. Acad. Sci. USA, 90:10188-10192 (1993).
Stern, A., et al., Purification to homogeneity and partial characterization of cytotoxic lymphcoyte maturation factor from human B-lymphoblastoid cells, Proc. Natl. Acad. Sci. USA, 87:6808-6812 (1990).
Tripp, C., et al., Interleukin 12 and tumor necrosis factor .alpha. are costimulators of interferon .gamma. production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist, Proc. Natl. Acad. Sci. USA, 90:3725-3729 (1993).
Wong, H., et al., Characterization of a Factor(s) which Synergizes with Recombinant Interleukin 2 in Promoting Allogeneic Human Cytolytic T-Lymphocyte Responses in Vitro, Cellular Immunology, 111:39-54 (1988).
Wu, C-Y., et al., IL-12 Induces the Production of IFN-.gamma. by Neonatal Human CD4 T Cells, J. Immunol., 151:1938-1949 (1993).
Gray, P., et al., Expression of human immune interferon cDNA in E. coli and monkey cells, Nature, 295:503-508 (1982).
Nagata, S., et al., Synthesis in E. coli of a polypeptide with human leukocyte interferon activity, Nature, 284:316-320 (1980).
Chan, S., et al., Induction of Interferon .gamma. Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers, J. Exp. Med., 173:869-879 (1991).
Cavalieri, R., et al., Synthesis of human interferon by Xenopus laevis oocytes: Two structural genes for interferons in human cells, Proc. Natl. Acad. Sci. USA, 74:3287-3291 (1977).
Bloom, E.T., and J. Horvath, Cellular and Molecular Mechanisms of the IL-12-Induced Increase in Allospecific Murine Cytolytic T Cell Activity, J. Immunol., 152:4242-4254 (1994).
Brunda, M., et al., Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors, J. Exp. Med., 178:1223-1230 (1993).
Cesano, A., et al., Cellular and Molecular Mechanisms of Activation of MHC Nonrestricted Cytotoxic Cells by IL-12, J. Immunol., 151:2943-2957 (1993).
Chan, S., et al., Mechanisms of IFN-.gamma. Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12), Role of Transcription and mRNA Stability in the Synergistic Interaction between NKSF and IL-2, J. Immunol., 148:92-98 (1992).
Familletti, P., et al., Production of High Levels of Human Leukocyte Interferon from a Continuous Human Myeloblast Cell Culture, Antimicrob. Agents & Chemother., 20:5-9 (1981).
Goeddel, D., et al., The Structure of eight distinct cloned human leukocyte interferon cDNAs, Nature, 290:20-26 (1981).
Manetti, R., et al., Interleukin 12 Induces Stable Priming for Interferon .gamma. (IFN-.gamma.) Production During Differentiation of Human T Helper (Th) Cells and Transient IFN-.gamma. Production in Established Th2 Cell Clones, J. Exp. Med., 179:1273-1283 (1994).
Nastala, C., et al., Recombinant IL-12 Administration Induces Tumor Regression in Association with IFN-.gamma. Production, The Journal of Immunology, vol. 153:1697-1706 (1994).
Kobayashi, M., et al., Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects on Human Lymphocytes, J. Exp. Med., 170:827-845 (1989).
Orange, J., et al., Effects of IL-12 on the Response and Susceptibility to Experimental Viral Infections, J. Immunol., 152:1253-1264 (1994).
Pestka, S., et al., Interferons And Their Actions, Ann. Rev. Biochem., 56: 727-77 (1987).
Alber Gottfried
Carr Jacqueline Anne
Mattner Frank Albert
Mulqueen Michael John
Palmer Kathrin
Buchholz Briana C.
Epstein William H.
Hoffmann-La Roche Inc.
Johnson George W.
Mertz Prema
LandOfFree
Use of IL-12 and IFN.alpha. for the treatment of infectious dise does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IL-12 and IFN.alpha. for the treatment of infectious dise, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IL-12 and IFN.alpha. for the treatment of infectious dise will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-875878